Johannesburg - The country's second-biggest pharmaceutical group, Adcock Ingram Holdings [JSE:AIP] advised on Friday that headline earnings per share for the year are expected to be between 29% and 32% higher than the previous corresponding year's figure of 354.8 cents.
Basic earnings per share for the year from continuing operations are expected to be between 27% and 30% higher than the previous year's figure of 354.9c.
In a trading statement, the group reminded shareholders that a non-tax deductible International Financial Reporting Standards 2 share-based payment expense of R269m was incurred in the 2010 financial year (equivalent to 154.8c per share in that year), in relation to the Adcock Ingram broad-based black economic empowerment transaction approved in a general meeting of shareholders on April 9 2010.
The group's financial results for the year ended September 30 2011 will be released on Sens on November 22.
Basic earnings per share for the year from continuing operations are expected to be between 27% and 30% higher than the previous year's figure of 354.9c.
In a trading statement, the group reminded shareholders that a non-tax deductible International Financial Reporting Standards 2 share-based payment expense of R269m was incurred in the 2010 financial year (equivalent to 154.8c per share in that year), in relation to the Adcock Ingram broad-based black economic empowerment transaction approved in a general meeting of shareholders on April 9 2010.
The group's financial results for the year ended September 30 2011 will be released on Sens on November 22.